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Germany; 13ICON Health Economics, Toronto, Ontario, CanadaA B S T R A C TObjectives: To assess how suitable current chronic obstructive pul-
monary disease (COPD) cost-effectiveness models are to evaluate
personalized treatment options for COPD by exploring the type of
heterogeneity included in current models and by validating outcomes
for subgroups of patients. Methods: A consortium of COPD modeling
groups completed three tasks. First, they reported all patient charac-
teristics included in the model and provided the level of detail in
which the input parameters were specified. Second, groups simulated
disease progression, mortality, quality-adjusted life-years (QALYs),
and costs for hypothetical subgroups of patients that differed in terms
of sex, age, smoking status, and lung function (forced expiratory
volume in 1 second [FEV1] % predicted). Finally, model outcomes for
exacerbations and mortality for subgroups of patients were validated
against published subgroup results of two large COPD trials. Results:
Nine COPD modeling groups participated. Most models included sex




ndence to: Martine Hoogendoorn, Institute for Med
otterdam, The Netherlands.mainly to specify disease progression and mortality. Trial results
showed higher exacerbation rates for women (found in one model),
higher mortality rates for men (two models), lower mortality for
younger patients (four models), and higher exacerbation and mortal-
ity rates in patients with severe COPD (four models). Conclusions:
Most currently available COPD cost-effectiveness models are able to
evaluate the cost-effectiveness of personalized treatment on the basis
of sex, age, smoking, and FEV1% predicted. Treatment in COPD is,
however, more likely to be personalized on the basis of clinical
parameters. Two models include several clinical patient character-
istics and are therefore most suitable to evaluate personalized treat-
ment, although some important clinical parameters are still missing.
Keywords: COPD, model, patient heterogeneity, validation.
Copyright & 2016, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Personalized medicine has the potential to improve the (cost-)
effectiveness of treatments and contribute to health care cost
containment. Hence, interest in personalized medicine has
increased exponentially in the past decade [1]. The concept ofpersonalized medicine has different definitions [2,3]. Some defi-
nitions focus on the use of genetics, proteomic, cytomic, and/or
metabolic biomarkers to define patient genotypes and pheno-
types most likely to benefit most from a certain treatment. Other
definitions are broader and refer to customizing treatment to the
individual characteristics, needs, and preferences of a patientociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ical Technology Assessment, Erasmus University Rotterdam, P.O.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 0 0 – 8 1 0 801during all stages of care, including prevention, diagnosis, treat-
ment, and follow-up [3]. The expectations of personalized med-
icine are high, but so far, the cost-effectiveness of such
technologies on average has not been found to be any better
than that of nonpersonalized interventions [4,5]. Thus, economic
evaluation studies are needed to show whether the personalized
approach indeed leads to greater efficiency in health care com-
pared with the one-size-fits-all approach.
If based on health economic models, such economic evalua-
tions of personalized treatment strategies based on demographic
and clinical patient characteristics require models that are able to
address the heterogeneity due to those patient characteristics
appropriately. However, most currently available cost-
effectiveness models are cohort Markov or state-transition mod-
els that have only limited capability for addressing patient
heterogeneity. Most published cost-effectiveness analyses sim-
ilarly focused on results for the average patient. Current guide-
lines for health economic modeling recognize the importance of
patient heterogeneity, but there is a lack of consensus on how to
best address this in a modeling framework [6].
One of the major chronic diseases for which treatment is
increasingly personalized is chronic obstructive pulmonary disease
(COPD). In 2011, the new Global Initiative for chronic Obstructive
Lung Disease guidelines proposed a new classification system for
patients with COPD based on lung function, symptoms, and exac-
erbations. Although this new classification is a step forward to
personalized treatment for COPD, proposed treatment guidelines for
the subgroups of patients still need to be validated [7]. Manufac-
turers of drugs and devices are increasingly focused on specific
phenotypes of patients, such as patients with frequent exacerba-
tions, a rapid decline in lung function, persistent systemic inflam-
mation, raised eosinophil concentrations, and bacterial colonization
[8,9]. In addition, caregivers providing multidisciplinary integrated
care programs develop different treatmentmodules for subgroups of
patients who need physical reactivation, smoking cessation support,
nutritional interventions, treatment of depression, and so forth. In
contrast, most decisions about the reimbursement of new treat-
ments are still made for large groups of patients and on the basis of
evaluations that do not consider patient heterogeneity. This is
expected to change rapidly because biologics for COPD are under
development [10] and payers are likely to limit the reimbursement
of these expensive drugs to specified subgroups. Moreover, new
drugs for COPD that have recently been launched or are still under
development are often quite similar to the currently marketed
drugs, which makes it increasingly difficult to demonstrate their
value for money unless one can specify the subgroup for which they
are particularly beneficial.
In the past years, several health economic decision models for
COPD have been published. In 2011, our modeling group took the
initiative to establish a network of people involved in COPD
modeling around the world (COPD modeling teams, pharmaceut-
ical companies interested in COPD modeling, epidemiologists,
clinicians, etc.). Up to now, we have organized three 1-day
meetings in 2011, 2012, and 2014 with the aim to compare the
different available models with respect to model structure and
input parameters and to cross-validate the models against each
other [11]. Proceedings of the third meeting regarding patient
heterogeneity are described in the present article.
The aim of this article was to assess how suitable current models
are to evaluate the cost-effectiveness of personalized treatment
options for COPD. First, we explored which type of patient hetero-
geneity is included in currently available COPD cost-effectiveness
models to see whether the models are able to evaluate subgroups of
patients with COPD that are considered clinically relevant. Second,
we investigated the impact of patient characteristics on the out-
comes. Finally, we validated the outcomes of specific subgroup
analyses with the models against subgroup results of clinical trialsto assess whether the models are suitable for performing subgroup
analyses. These questions are relevant because most of the models
are initially built to evaluate treatment options for a large group of
patients with COPD.Methods
Procedure
In March 2014, the COPD modeling groups that participated in
previous meetings as well as new groups identified through
publications or other participants within the network were
contacted to explore their interest in participation in the third
COPD modeling meeting and in running the model simulations
required for this heterogeneity analysis. Modeling groups were
first asked to specify which patient characteristics are currently
included in their model and which input parameters are specified
by subgroup. Second, they were asked to run their model for
hypothetical patients who differed in terms of patient and
disease characteristics to explore the impact of these character-
istics on the outcomes of the models. Third, they were asked to
simulate the outcomes for subgroups of patients that had similar
characteristics as the subgroups of two large randomized con-
trolled clinical trials to validate the model outcomes. Results
were returned to the organizers of the meeting in a structured
format in Microsoft Excel 2 weeks before the meeting. The
combined results of the models were circulated to all participants
of the COPD modeling meeting 1 week before the meeting to give
participants time to reflect on the outcomes. The results were
presented during the meeting and explanations for the differ-
ences in outcomes between the models were discussed.
Participating Models
Nine COPD models participated in the model simulations. Six of
these nine models also participated in the previous meeting in
2012 [12–17]. A short description of these six models can be found
in the publication about the proceedings of this second COPD
modeling meeting [11]. Three new models also participated. The
simulation model of Asukai et al. [18] was published in 2013. The
other two models have not yet been published, but have been
presented at international conferences. The model of Briggs et al.
(GALAXY COPD model) was presented at the ISPOR Annual
International meeting 2013 and the ISPOR 17th Annual European
Congress 2014 [19,20]. The model of Dal Negro [21] was also
presented at the ISPOR 17th Annual European Congress 2014 [21].
Content of the Modeling Challenge
For the first part of the modeling challenge, groups reported all
patient characteristics that are currently included in their mod-
els. Furthermore, groups provided the level of detail in which the
following input parameters had been specified in the models:
disease progression, exacerbation frequency, mortality, case-
fatality of an exacerbation, utilities during stable disease, utilities
during exacerbations, maintenance costs, and exacerbation-
related costs.
In part two, modeling groups simulated the outcomes for
hypothetical subgroups of patients that differ in terms of sex, age,
smoking status, and level of forced expiratory volume in 1 second
(FEV1) % predicted to see how patient heterogeneity affected
effects and costs within one model and between models. Sex,
age, smoking status, and FEV1% predicted were chosen because
these are the factors that are included in most models. In the first
simulation, outcomes for a 65-year-old, ex-smoking, male patient
with severe COPD were calculated. In each of the following four
simulations, one of the patient characteristics was changed:
Table 1 – Baseline characteristics of subgroups within the placebo group of the UPLIFT and TORCH trials used as
starting population of the model simulations [24–27].
Characteristic UPLIFT trial TORCH trial
By sex By age By smoking status By COPD severity








N 2222 784 172 432 1791 535 775
Sex: males (%) 100 0 58 62 78 72 76
Age (y), mean  SD 65  8 62  9 o50 61  9 66  9 65  9 65  8
Current smokers (%) 26 40 57 100 0 47 43
Postbronchodilator FEV1% predicted,
mean  SD
47  13 49  13 47  15 50  15 46  15 59  7 40  6
GOLD II: moderate COPD (%) 44 48 48 54 41 100 0
GOLD III: severe COPD (%) 45 43 36 38 48 0 100
GOLD IV: very severe COPD (%) 10 7 15 7 10 0 0
COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; TORCH, TOwards a Revolution in
COPD Health; UPLIFT, Understanding Potential Long-Term Impacts on Function with Tiotropium.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 0 0 – 8 1 0802female instead of male patient, 75-year-old instead of 65-year-old
patient, smoking instead of ex-smoking patient, and patient with
moderate COPD instead of severe COPD. The outcomes of each of
these four simulations were compared with the results of the first
simulation.
In part three, the validity of the subgroup analyses with the
models was investigated by comparing the model outcomes
against published subgroup results of two large randomized
controlled clinical trials, the 4-year Understanding Potential
Long-Term Impacts on Function with Tiotropium (UPLIFT) trial
and the 3-year TOwards a Revolution in COPD Health (TORCH)
trial [22,23]. In the UPLIFT trial, almost 6000 patients with
moderate-to-very severe COPD were randomized to placebo,
defined as all regular respiratory medications except inhaled
anticholinergics, or tiotropium 18 mg plus all regular respiratory
medications except other inhaled anticholinergics [22]. In the
TORCH trial, slightly more than 6000 patients with moderate-to-
very severe COPD were randomized to placebo, defined as all
COPD medications except long-acting bronchodilators and
inhaled corticosteroids, salmeterol 50 mg, fluticasone 500 mg, or
the combination of salmeterol 50 mg and fluticasone 500 mg [23].
For both the UPLIFT trial and the TORCH trial, several subgroup
analyses have been published mainly by sex, age, smoking status,
and level of FEV1% predicted [24–27]. The modeling groups were
asked to adjust the starting population of the model to the
baseline characteristics of the specific subgroups within the
placebo group of the trial in terms of percentage of males, mean
age, percentage of current smokers, and mean FEV1% predicted
(or distribution over the GOLD severity stages moderate, severe,
or very severe COPD). The baseline characteristics of the sub-
groups in the trial are presented in Table 1. For comparison with
the UPLIFT trial placebo arm, groups were asked to run the
simulations assuming that patients received all regular respira-
tory medications except inhaled anticholinergics. Simulation of
the TORCH trial placebo arm was done assuming that patients did
not use long-acting bronchodilators and inhaled corticosteroids.Outcomes
For part two of the challenge, the following outcomes were
reported: disease progression defined as decline in lung function,
mortality, quality-adjusted life-years (QALYs) per patient, and
total costs per patient. These outcomes were calculated for both
1-year and lifetime horizons. For part three of the challenge, thetotal number of exacerbations per patient-year and all-cause
mortality was calculated including the uncertainty around the
outcomes if possible. The time horizon of the model simulations
was similar to the duration of the clinical trials: 3 years for the
TORCH trial and 4 years for the UPLIFT trial.Results
Table 2 presents the patient characteristics included in the nine
participating cost-effectiveness models. Most models include sex,
age, smoking status, and FEV1% predicted. Newer models also
included patient characteristics such as previous exacerbations,
body mass index (BMI), and comorbidities (Asukai_simulation
model and Briggs). Table 3 presents the level of specification for
the most important input parameters. The level of detail in which
the input parameters are specified varies greatly between the
models. Table 4 presents the results for the model simulations of
hypothetical patients who differ in terms of sex, age, smoking
status, and FEV1% predicted. The validation of subgroup analysis
in the models against the outcomes of the subgroup analyses in
the clinical trials is presented in Figures 1 to 4. In subsequent
sections, the results will be discussed separately for the four
patient characteristics that most of the models have in common:
sex, age, smoking status, and FEV1% predicted. For each charac-
teristic we first present the results for the simulations of hypo-
thetical patients followed by the simulations of the subgroups in
the clinical trials.
Sex
Seven models included sex as patient characteristic (Asukai_-
Markov, Asukai_simulation, Briggs, Dal Negro, Hoogendoorn,
Samyshkin, and Wacker). Sex was mainly included to specify
disease progression (six models) and mortality (six models)
(Asukai_Markov, Asukai_simulation, Briggs, Dal Negro, Hoogen-
doorn, and Samyshkin) (Table 3). Results of the comparison of
hypothetical subgroups of patients showed, however, that three
of the models that included sex reported a disease progression
rate that was similar for men and women (Asukai_Markov,
Dal Negro, and Hoogendoorn) (Table 4), whereas three models
had faster disease progression rates for women (Asukai_simula-
tion, Briggs, and Samyshkin). Five models had a higher 1-year
mortality rate for male patients than for female patients
(Asukai_Markov, Asukai_simulation, Brigs, Hoogendoorn, and







Hansen Hoogendoorn Samyshkin Wacker
Sex X X X X X X X
Age X X X X X X X X X
Smoking X X X X X X
FEV1 % predicted X X X X X X X X X
Height X
Previous exacerbations X X X
BMI X X
Comorbidities X X X
No. of ER visits/hospitalizations X
Rapid decline in FEV1 X X
Dyspnea (mMRC) X








BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO, diffusion lung capacity for carbon monoxide; ER, emergency room; EQ-5D, EuroQol five-dimensional questionnaire;





























Table 3 – Level of specification of important input parameters.
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BODE, Body-mass index, airflow Obstruction, Dyspnea and Exercise index; DLCO, diffusion lung capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; pred., predicted; RV, residual
volume.




























Table 4 – One-year model outcomes for a hypothetical reference patient (analysis 1) and for patients who differ on one patient characteristic compared
with the reference patient (analyses 2–5).
Analysis Model
Asukai_Markov Asukai_simulation Borg* Briggs Dal Negro Hansen Hoogendoorn Samyshkin Wacker
1. Male patient, 65 y, ex-smoking with severe COPD (¼comparator)
Disease progression (%)† 12.8 0.4 5.5 –0.51 pred. 10.0 5.2 2.8 11.9 2.5
Mortality (%) 4.0 4.7 7.2 2.8 10.0 3.1 7.1 4.9 12.4
QALYs 0.752 0.627 0.688 0.581 NA 0.658 0.723 0.724 0.520
Costs (2014 $) 1950 1560 2350 3830 2680–4020 2260 1680 2270 2480
2. Female patient, 65 y, ex-smoking with severe COPD
Disease progression (%)† 12.8 0.9 ‡ –0.81% pred. 10.0 ‡ 2.8 16.7 2.5
Mortality (%) 3.6 3.3 ‡ 2.6 10.0 ‡ 4.7 4.9 7.9
QALYs 0.754 0.406 ‡ 0.623 NA ‡ 0.723 0.721 0.530
Costs (2014 $) 1950 1590 ‡ 3090 2680–4020 ‡ 2050 2320 2540
3. Male patient, 75 y, ex-smoking with severe COPD
Disease progression (%)† 11.4 0.5 5.6 –0.57 pred. 20.0 5.2 3.6 11.6 2.1
Mortality (%) 6.1 13.8 24.1 5.5 20.0 9.3 13.2 12.2 27.2
QALYs 0.742 0.598 0.624 0.593 NA 0.643 0.723 0.696 0.470
Costs (2014 $) 1900 1460 2090 4010 4020–5360 2200 2090 2180 2290
4. Male patient, 65 y, smoking with severe COPD
Disease progression (%)† 12.8 2.3 ‡ –1.27% pred. ‡ 8.6 3.6 ‡ 7.6
Mortality (%) 4.0 4.8 ‡ 3.6 ‡ 3.1 8.1 ‡ 17.7
QALYs 0.752 0.627 ‡ 0.548 ‡ 0.657 0.723 ‡ 0.500
Costs (2014 $) 1950 1600 ‡ 3840 ‡ 2270 1680 ‡ 2450
5. Male patient, 65 y, smoking with moderate COPD§
Mortality (%) 2.5 3.3 5.3 1.7 8.0 2.5 5.0 3.0 6.3
QALYs 0.781 0.653 0.741 0.623 NA 0.702 0.737 0.772 0.570
Costs (2014 $) 330 450 1060 3910 2010–2680 1580 1270 1540 1460
COPD, chronic obstructive pulmonary disease; NA, not available for this model; pred., predicted; QALY, quality-adjusted life-year.
* The runs from this model reflect a prevalent mix of 52% male patients and 48% female patients, of which 41% are current smokers.
† Disease progression was defined as the percentage of patients with severe COPD moving to very severe COPD except for the model of Briggs et al. in which disease progression was defined as the
decline in FEV1% predicted.
‡ Subgroup analysis not possible for this model.
§ For this subgroup, disease progression is not a relevant outcome because the percentage of patients with moderate COPD moving to severe COPD is not comparable with the first subgroup




















































Fig. 1 – Comparison of model results for the subgroup sex with empirical results of the 4-year UPLIFT trial for (A)
exacerbations and (B) all-cause mortality. *Difference is statistically significant. Difference in the simulation model of Asukai
could not be tested because no uncertainty was available around the estimates. UPLIFT, Understanding Potential Long-Term
Impacts on Function with Tiotropium.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 0 0 – 8 1 0806Wacker), whereas in one model mortality rate in men and women
was comparable (Samyshkin). A few models specified utilities during
stable disease and/or COPD-related maintenance costs by sex
(Table 3) (Asukai_simulation, Briggs, and Hoogendoorn). The simu-
lationmodel of Asukai et al. specifying utility weights by sex reported
a lower number of QALYs for a female patient than for a male
patient, despite a lower female mortality, whereas the model of
Briggs et al. had a slightly higher number of QALYs for female
patients. Of the two models specifying maintenance costs by sex,
one used higher costs for women (Hoogendoorn), whereas the other
model (Briggs) included lower costs for women than for men.
Validation of the model results with respect to sex against empirical
data showed that in the UPLIFT study male patients had fewer
exacerbations (rate ratio [RR] ¼ 0.89; 95% confidence interval [CI]
0.81–0.98) compared with female patients, whereas this was found
only in themodel of Briggs (Fig. 1A). The other models reported equal
rates for women and men. Four-year all-cause mortality in the
UPLIFT trial was reported to be higher for men (RR ¼ 1.49; 95% CI
1.21–1.84)), which was found in two models (Hoogendoorn and
Wacker) (Fig. 1B).Age
All nine participating models included age as characteristic mainly to
specify disease progression (seven models) and mortality (nine
models). In one model, disease progression was lower for a 75-















Fig. 2 – Comparison of model results for the subgroup age with em
and (B) all-cause mortality. *Difference is statistically significant
tested because no uncertainty was available around the estima
Function with Tiotropium.the models of Dal Negro and Hoogendoorn, disease progression
increased with increasing age, whereas in the remaining models
disease progression was about equal for both ages (Table 4). In all
models, 1-year mortality was higher for a 75-year-old patient than
for a 65-year-old patient (1.5-3.3 times higher). Only one model
reported higher QALYs for an older patient (Briggs). Three of the
four models that specified costs by age (Briggs, Dal Negro, Hoogen-
doorn, andWacker) reported higher costs for an older patient (Briggs,
Dal Negro, and Hoogendoorn). Validation of the model results with
respect to age against the outcomes of the UPLIFT study showed that
in all models except one, the exacerbation rate in the subgroup of
patients younger than 50 years was equal to the exacerbation rate in
the total population (mean age 65 years), which was in accordance
with the trial results (Fig. 2A). Only in the model of Briggs, the
subgroup of patients younger than 50 years had a significantly lower
exacerbation rate than did the total population. In the subgroup of
younger patients in the UPLIFT study, 4-year all-cause mortality was
significantly lower compared with that of the total population (RR ¼
0.43; 95% CI 0.25–0.74), which was also found in four models (Briggs,
Hansen, Hoogendoorn, and Wacker) (Fig. 2B).Smoking Status
Six of the nine models included smoking status as patient
characteristic (Asukai_Markov, Asukai_simulation, Briggs, Han-
sen, Hoogendoorn, and Wacker). In all six models, disease













pirical results of the 4-year UPLIFT trial for (A) exacerbations
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Fig. 3 – Comparison of model results for the subgroup smoking status with empirical results of the 4-year UPLIFT trial for (A)
exacerbations and (B) all-cause mortality. *Difference is statistically significant. Difference in the simulation model of Asukai
and the trial (exacerbations) could not be tested because no uncertainty was available around the estimates. Uplift,
Understanding Potential Long-Term Impacts on Function with Tiotropium.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 0 0 – 8 1 0 807having a higher disease progression compared with ex-smokers
(Table 4). Three models specified mortality by smoking status
(Briggs, Hoogendoorn, and Wacker). One-year mortality in these
models was higher for smokers (Table 4). Only in the model of
Briggs et al., smoking status was modeled to have an association
with other input parameters such as utilities and costs (Table 3).
As a result, the 1-year QALYs and costs were (almost) equal for a
patient who smoked compared with an ex-smoking patient in the
models (Table 4). The UPLIFT study showed no difference in
exacerbations between smokers and ex-smokers, which was in
line with the results of most models, except for two (Briggs and
Wacker) that reported a higher exacerbation rate for ex-smokers.
Four-year mortality in the UPLIFT trial was also not found to be
different between smokers and ex-smokers. Three models, how-
ever, reported a significantly higher mortality rate for ex-smokers
than for smokers (Hansen, Hoogendoorn, and Wacker), most
likely because ex-smokers in the UPLIFT trial were older than
the smokers and not because of their difference in smoking
status. This is confirmed by Table 4, which isolates the impact
of smoking status from the impact of age.FEV1% predicted
All nine models included FEV1% predicted. In all models except















Fig. 4 – Comparison of model results for the subgroup FEV1% pre
exacerbations and (B) all-cause mortality. *Difference between m
†Difference is most likely statistically significant, but standard e
Asukai and the model of Dal Negro could not be tested because
chronic obstructive pulmonary disease; TORCH, TOwards a RevFEV1% predicted. All models used FEV1% predicted to specify
exacerbation frequency, mortality, utilities, and maintenance
costs. In all nine models, 1-year mortality and costs were lower
for a patient with moderate COPD (FEV1% predicted about 65%)
than for a patient with severe COPD (FEV1% predicted about 40%),
while the number of QALYs was higher in all models (Table 4).
Five models also specified utilities during exacerbations by FEV1%
predicted (Briggs, Borg, Dal Negro, Hansen, and Wacker). Exacer-
bation costs were specified by FEV1% predicted by four models
(Briggs, Dal Negro, Hansen, and Wacker) (Table 3).
Validation of the model results with respect to FEV1% predicted
against the outcomes of the 3-year TORCH study showed that in
three models (Borg, Briggs, and Wacker) the exacerbation rate in
patients with severe COPD was significantly higher than in patients
with moderate COPD (Fig. 4A), which was in line with the trial
results. In the TORCH trial, mortality in patients with severe COPD
was higher than in patients with moderate COPD (RR ¼ 1.33; 95% CI
1.09–1.63). Four models reported a higher mortality rate in patients
with severe COPD (Borg, Hansen, Hoogendoorn, and Wacker).Discussion
By comparing patient heterogeneity in currently available COPD
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oderate and severe COPD is statistically significant.
rrors were missing. Difference in the simulation model of
no uncertainty was available around the estimates. COPD,
olution in COPD Health.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 0 0 – 8 1 0808suitable current models are to evaluate the cost-effectiveness of
personalized treatment options for COPD. The patient character-
istics that almost all nine models included were sex, age,
smoking status, and FEV1% predicted.
Results with respect to sex showed that the empirical data
supported a difference in exacerbations between female and
male patients. Several studies in the literature confirm that
female patients have a higher exacerbation rate than do male
patients [28–31]. Only one of the current COPD models included
this relationship. Two models reported a significantly higher
mortality rate in male patients, which was also found in the
UPLIFT trial. However, it should be noted that in the trial female
patients were on average 3 years younger and had a slightly
higher FEV1% predicted, but they were also more likely to smoke.
The difference in mortality is less clear from the literature. Some
studies reported lower mortality rates for women [32–34],
whereas others found no difference [35–38]. Only two models
specified quality of life by sex, whereas several studies found a
lower quality of life for female patients [39–41].
All models included a strong association between age and
mortality, which was in line with studies found in the literature
[32,33,35–38]. Validation against trial results also showed a differ-
ence in mortality between young and old patients for the trial as
well as most models. Most models did not specify quality of life
by age, whereas several studies have shown that older patients
with COPD have a lower quality of life [39,42]. Three models
specified COPD-related costs by age. Several studies investigated
the association between age and COPD-related costs and found
no significant impact of age on costs [43–46]. This may be because
age and FEV1% predicted are correlated and in three of these
studies FEV1% was also included in the multivariate model and
found to be a significant predictor.
The impact of smoking on disease progression was included in
six of the models. Smokers were modeled to have a higher disease
progression compared with ex-smokers, which was in line with the
literature [47–49]. Three models included a higher all-cause mortality
rate for smokers than for ex-smokers in their input data (Table 4). No
difference in mortality rate between smokers and ex-smokers was
found in the UPLIFT trial. Validation of model outcomes against trial
results showed that three models reported a higher mortality rate for
ex-smokers. This was probably because ex-smokers in the trial were
on average 5 years older than smokers and had a lower FEV1%
predicted. Of 17 studies on predictors of mortality found in the
literature, 4 studies found a higher mortality rate for smokers, 6
studies found no association, and 10 studies did not investigate this
association.
With respect to FEV1% predicted, the models are in line with the
empirical data and the literature. All models include an association
between FEV1% predicted and exacerbation frequency, quality of life,
mortality, and costs. In some models, the differences in exacerba-
tions andmortality are however very small and not significant due to
the large uncertainty around the estimates. The literature also
showed that disease progression in terms of lung function decline
seems to decrease when the FEV1 decreases [47,48,50]. This associ-
ation was not included in all models, because five of themodels used
the Lung Health Study as (one of the) data source (s) for disease
progression, which is a study in patients with mild-to-moderate
COPD showing the opposite relation (decline increases when FEV1
decreases) [49]. It is not surprising that the model performance with
respect to patient heterogeneity was best for FEV1% predicted,
because in almost all models the FEV1% predicted is the key
parameter. Five of the nine models are cohort Markov models with
Markov states defined according to the 2007 GOLD classification; that
is, the severity of COPD was defined by the FEV1% predicted.
Outcomes of the different models were compared with pub-
lished subgroup results of two large trials: the UPLIFT and TORCH
trials. Some of the COPD models were built to extrapolate theresults of clinical trials (Asukai_Markov and Samyshkin) and
were populated with input data from these trials, whereas other
models are population models using a wide range of different
data sources as input (Hoogendoorn, Hansen, and Wacker). For
the latter models, comparison with trial results may therefore be
less valid because it is well known that patients included in
clinical trials are a subgroup of the total COPD population. This
was, for example, shown in a study of Kruis et al. [51] that found
that patients participating in large clinical trials sponsored by
pharmaceutical companies are on average younger, more likely
to be male, have a lower FEV1% predicted, and tend to have more
exacerbations than do patients in primary care. In the current
analysis, this selection bias issue was most likely the explanation
that no difference in mortality was found between smokers and
ex-smokers in the UPLIFT trial. Patients who continue to smoke
are probably less likely to be included in clinical studies because
they progress faster to more severe stages, have more comorbid-
ities, and are more likely to die because of other smoking-related
diseases. Nevertheless, among the patients who continue to
smoke despite having COPD there may be relatively more
patients who are less susceptible to smoking-related diseases.
The true impact of trial populations being a selective group of
patients on the outcomes of this study is difficult to assess. In the
present study, we mainly focused on differences in outcomes
between subgroups within one model or trial and therefore the
impact might be limited.
The results of this study showed that all currently available
models are capable of running simulations for different age- and
COPD severity classes. Most models also have the ability to run
analyses separately for men and women and for smokers and ex-
smokers. The validity of these subgroup analyses within the models
is questionable, because important input parameters have not been
specified by sex, age, or smoking status. For example, the specifica-
tion of higher exacerbations for women or lower quality of life with
older age is not included inmost models. Most models are developed
to evaluate treatment options for the total general COPD population
or the average COPD trial population.
Although it is not unlikely that future treatment will be increas-
ingly tailored to age, sex, and smoking status, treatment is more
likely to be personalized on the basis of clinical parameters especially
when considering ethical debates and societal preferences. Exacer-
bations, for example, are highly associated with the number of
previous exacerbations [29–31,52]. Mortality in COPD is associated
not only with age and FEV1 but also with comorbidities, BMI,
dyspnea, and several other clinical parameters [32,34,36,38,53]. BMI
also seems to be associated with quality of life in COPD [39,54] and
comorbidities may affect COPD-related costs [44,45,55,56]. Only the
more recently developed models of Asukai (simulation) and Briggs
included these types of clinical parameters and are therefore more
suitable than the other models to evaluate personalized treatment.
Recent reviews on phenotyping in COPD showed that currently about
four phenotypes have been defined in COPD that may require a
different treatment strategy: emphysema, COPD with chronic bron-
chitis, COPD combined with asthma, and COPD with frequent
exacerbations [57–60]. Information on effectiveness and cost-
effectiveness of treatment options for these subgroups is needed to
guide clinical guideline development and decisions for reimburse-
ment. Three of the nine models included information on one of the
phenotypes, that is, COPD with frequent exacerbations, but none of
the currentmodels is able to evaluate treatment options for the other
three phenotypes. Future models should include all clinical patient
characteristics currently considered to influence disease severity,
prognosis, and treatment response in COPD.
The present study had some limitations. First, not all models
could perform uncertainty analysis around the results for exac-
erbations and all-cause mortality. Therefore, it was not always
possible to determine whether predicted differences between
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 0 0 – 8 1 0 809subgroups are important within the range of uncertainty esti-
mated. The information in the published articles of the two
clinical trials was also sometimes not sufficient to calculate
whether the difference between subgroups was statistically sig-
nificant or not. Results of the trials by smoking status and by
COPD severity did not present SDs or standard errors around the
mean exacerbation rate [24,27]. The exacerbation rates in the
UPLIFT trial in smokers and ex-smokers were, however, almost
equal, 0.77 versus 0.83, a difference that is most likely not
significant [27]. In contrast, the difference in exacerbation rate
in the TORCH trial between people with severe and moderate
COPD was large, 1.24 versus 0.82, and therefore this difference
seems significant given the population size [24].
A second limitation was that the starting population of the
models was adjusted only with respect to sex distribution, age,
smoking distribution, and FEV1%predicted to mirror the population
of either the TORCH trial or the UPLIFT trial. The most recent models
include much more characteristics (e.g., BMI and comorbidities) that
could have been adjusted to create model populations that were
even more similar to the trial populations. However, this would have
made a comparison with the other models impossible.
A third limitation of the present study was that we only
assessed whether there were significant differences in outcomes
between the subgroups simulated with the models and whether
that result was in line with the trial results and the literature. We
did not focus on the results of the models in absolute terms.
However, the results of the different models showed substantial
variation, especially for mortality. A more detailed external
validation of model results against the outcomes of the trials
for the total population will be a topic of another article.
Finally, although this study aimed to compare cost-
effectiveness models, it mainly focused on the comparison of
clinical outcomes, not on costs. Only Table 4 presents informa-
tion on costs. Validation of costs was not possible because the
trials did not present costs specified by subgroups. Clinical
outcomes are important outcomes for cost-effectiveness models
as well because they have a high impact on quality of life
and costs.
In conclusion, this study showed that most currently available
COPD cost-effectiveness models include the relevant patient
characteristics sex, age, smoking status, and FEV1% predicted
and are therefore able to evaluate the cost-effectiveness of
personalized treatment based on these parameters. Most models,
however, do not include all important associations between these
characteristics and input parameters. Furthermore, treatment in
COPD is more likely to be personalized on the basis of clinical
parameters. Two models also included several clinical patient
characteristics, such as previous exacerbations, BMI, and comor-
bidities, and seem to be more suitable to evaluate personalized
treatment. Inclusion of other clinical parameters, such as emphy-
sema, chronic bronchitis, and coexistence of asthma, is relevant
to make the models suitable to evaluate the cost-effectiveness of
treatment options for currently defined phenotypes in COPD.
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